Publications by authors named "M Menzen"
Introduction: To investigate outcomes in adults with type 2 diabetes who switched to once-weekly (OW) semaglutide from another glucagon-like peptide-1 receptor agonist (GLP-1RA) in clinical practice.
Methods: This post hoc analysis used data from the SemaglUtide Real-world Evidence (SURE) program, which included nine observational studies investigating the initiation of OW semaglutide in people with type 2 diabetes in routine clinical practice. Using a random coefficient-adjusted mixed model for repeated measurements, changes in glycosylated hemoglobin (HbA), body weight, and body mass index were analyzed for GLP-1RA-experienced patients who had at least one documented HbA value within the 12 weeks before switching to OW semaglutide.
Article Synopsis
- The study aimed to assess the safety of once-weekly semaglutide in adults with type 2 diabetes (T2D) through analysis of nine real-world studies, complementing earlier randomized clinical trials.
- In the analysis of 3,505 patients, 24.3% experienced adverse events, primarily mild gastrointestinal issues, with minimal serious reactions recorded.
- The overall safety profile of semaglutide was consistent with previous findings from phase 3 trials, indicating it is well tolerated among diverse groups of T2D patients in routine practice.
[It's a new world: Improvement of diabetes therapy through digital and technical innovations].
Dtsch Med Wochenschr
March 2023
Medical progress is increasingly characterized by digital and technical solutions that improve and facilitate treatment of our patients. Especially diabetes therapy is an ideal field for digital and technical solutions. The complexity of insulin therapy with the need to take multiple variables into account is a brilliant example for the use of digital support processes.
View Article and Find Full Text PDFContext: Efficacy and safety of once-weekly semaglutide in type 2 diabetes were established in the phase 3 SUSTAIN trials, which included patients across the continuum of type 2 diabetes care. It is useful to complement these findings with real-world evidence.
Objective: SURE Germany evaluated once-weekly semaglutide in a real-world type 2 diabetes patient population.